Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

New agency

- PMLiVE

FDA approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

GSK’s Jemperli combination shows promise in phase 3 endometrial cancer trial

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

WHO publishes new infodemic management tools for pandemic preparedness

The taxonomy will support pandemic planning for respiratory pathogen disease events

- PMLiVE

Pfizer and BioNTech’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

Did somebody say AI?

Things are moving rapidly and we are currently only scratching the surface of AI’s possibilities

Psoriasis-Awareness-Day

Listening and hearing – how patients’ online behaviour can help us to improve wellbeing in psoriasis.

The following article was developed using information gathered through primary and secondary desk research, including a recent Social Listening project conducted by our team at Mednet.

Mednet

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval for ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Roche collaborates with Ibex and Amazon Web to improve cancer diagnosis

Integrated artificial intelligence-based tools will support clinicians’ decisions in cancer diagnosis

- PMLiVE

University of Oxford launches new trial to enhance flu and COVID-19 vaccines

Results from the study are expected to help increase the protection of future vaccines

- PMLiVE

The impact of cell therapies on cancer treatments

PME talks to Matt Angel, CEO of Eterna Therapeutics, about how research using cell therapies to treat cancer has improved in the last decade, and how these therapies benefit patients

Create Long-lasting KOL Relationships, benefits of virtual advisory boards

Here's another top reason why virtual advisory boards are simply better than in-person and hybrid advisory boards. #4. More Frequent Interactions and Long-lasting KOL Relationships Another important benefit of online...

Impetus Digital

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links